INTRODUCTION
Peripheral arterial disease (PAD) is an atherosclerotic syndrome in which the lumen of the arteries in the lower extremities becomes progressively obstructed by plaque. Recent epidemiologic studies estimate a prevalence of PAD of 11 to 16% in the population aged 55 or older [1] [2] [3] , and a prevalence as high as 20 to 30% in specific high-risk populations [4] [5] [6] .
Early detection of PAD is essential to prevent subsequent cardiovascular morbidity and mortality. Several prospective and cross-sectional studies have shown that PAD is a marker for arterial disease in other vascular beds [7] [8] [9] [10] and is associated with a six-fold increase in fatal and nonfatal myocardial infarction [11] [12] [13] and a two-to three-fold increase in risk of ischemic stroke [14] [15] [16] . In addition, the presence of PAD is a strong predictor of overall mortality [17] [18] [19] .
Intermittent claudication, defined as reproducible pain in the lower limbs during exercise relieved by rest, is the most common manifestation of symptomatic PAD 20 . The Framingham Heart Study initially described the association between intermittent claudication and both coronary heart disease and stroke and reported a two-fold age-adjusted increased risk of death in both men and women with claudication 21 . However, up to one-third of patients do not even alert a physician to their leg symptoms 22 , and fewer than half of general medicine physicians report routinely obtaining a history of claudication 23 . Furthermore, in patients with an already established diagnosis of PAD, physician awareness of the diagnosis is low 5 . The ankle-brachial index (ABI), a non-invasive method used to assess the lower extremity arterial system, is considered the best PAD screening test 24, 25 . Recent PAD management guidelines recommend screening ABIs in high-risk patients in the primary care setting 26 . However, major barriers currently prevent widespread implementation of this practice 27 , and as a result, PAD remains under-diagnosed and under-treated in the general population. Therefore, we sought to determine whether self-reported PAD, defined as an affirmative response to one of two simple questions regarding exertional leg symptoms or a prior diagnosis of PAD, would help identify those patients who may be at higher risk for future vascular events.
METHODS
The Northern Manhattan Study (NOMAS) is an ongoing, prospective, population-based epidemiological study designed to determine stroke incidence, risk factors, and outcomes in a multi-ethnic, urban population of northern Manhattan, NY. In 1990, 71% of the 210,000 individuals who resided this area were ≥20 years of age; 22% were white, 13% were black, and 64% were Hispanic.
Participants
The methods of subject recruitment and enrollment into NOMAS have been described elsewhere 28, 29 . Briefly, random digit dialing of approximately 25,000 households was performed, and community participants were enrolled in NOMAS if they: (1) had never had a stroke, (2) were older than age 40, and (3) had resided in Northern Manhattan for ≥3 months in a household with a telephone. Ninety-one percent of those called participated in a telephone interview, and 75% of those who were eligible and invited to participate came to Columbia University Medical Center (CUMC) for an in-person evaluation (overall participation rate 68%). The study was approved by the Institutional Review Board at CUMC. All participants gave consent directly or through a surrogate when appropriate. The final cohort consisted of 3,298 participants, and 3,290 answered the self-reported PAD questions. Of those, 313 had a history of myocardial infarction (MI) and were thus excluded from this analysis. The final cohort included in this analysis consisted of 2,977 participants.
Procedures
Standardized questions were adapted from the Behavioral Risk Factor Surveillance System by the Centers for Disease Control 30 regarding hypertension, diabetes, cigarette smoking, and cardiac conditions. Blood pressure was measured with mercury sphygmomanometers and cuffs of appropriate size. Hypertension was defined as a blood pressure ≥140/ 90 mmHg (based on the average of two measurements during one sitting by a trained research assistant), the patient's self-report of hypertension, or antihypertensive medication use. Diabetes mellitus was defined by the patient's self-report of such a history, use of insulin or oral antidiabetic medication, or fasting glucose ≥126 mg/dl. Lipid profile was measured at the time of enrollment. Smoking was defined as having smoked more than 100 cigarettes in a lifetime or currently smoking. Moderate alcohol intake was defined as >0 drinks per week but ≤2 drinks per day in the past year as previously described 31 . Prior coronary revascularization was defined as a history of balloon angioplasty, stenting, and/or coronary artery bypass surgery. Assessments were conducted in English or Spanish, depending on the primary language of the participant. Raceethnicity was based on self-identification through a series of interview questions modeled after the US census and conformed to the standard definitions outlined by Directive 15.
Self-Reported Peripheral Arterial Disease
Peripheral arterial disease was self-reported and defined as an affirmative answer to either of the two following questions:
1. Do you get pain in the back of your legs when you walk that stops with rest? 2. Have you been told you have vascular (arterial) disease in the legs?
Annual Prospective Follow-Up All subjects were prospectively followed annually by telephone. Subjects were interviewed and screened for changes in vital status, neurological and cardiac symptoms and events, and any interval hospitalizations. Any subject who screened positive by telephone was scheduled for an in-person assessment. All affirmative responses to neurological symptoms and conditions were reviewed and the subjects examined by a study neurologist.
In addition, active hospital surveillance of admission and discharge International Classification of Diseases, Ninth Revision (ICD-9) codes at CUMC provided data on mortality and morbidity that may not have been captured during annual telephone follow-up. Review of discharge lists from outside hospitals and contacts with community physicians and visiting nurse services were also performed for surveillance of events. The overall loss to follow-up rate was minimal (<1%).
Outcome Classifications
Stroke was defined by the World Health Organization criteria as "rapidly developing clinical signs of focal (at times global) disturbance of cerebral function, lasting more than 24 h or leading to death with no apparent cause other than that of vascular origin." 32 Ischemic stroke was defined as nonhemorrhagic cerebral infarction. Stroke subjects had a battery of standard diagnostic tests including brain imaging. Medical records of all hospitalizations were reviewed to verify details of suspected events. Two study neurologists classified the strokes independently after review of all available data. For subjects who died, the date of death was recorded along with cause of death. Deaths were classified as vascular or nonvascular based on information obtained from the family, medical records, and death certificate. Causes of vascular death included stroke, MI, heart failure, pulmonary embolus, cardiac arrhythmia, and other vascular causes. Nonvascular causes of death included accident, cancer, pulmonary (e.g., pneumonia or chronic obstructive pulmonary disease), and other nonvascular causes.
Statistical Analyses
The prevalence of self-reported PAD (srPAD) was calculated overall and by race-ethnic groups. The frequency of vascular risk factors was compared between those with and without srPAD using the chi-square test for categorical variables and the t-test for continuous variables. The Kaplan-Meier curves and log rank test were used for comparing the incidence of combined vascular events (ischemic stroke, MI, and vascular death) between those with and without srPAD. Cox proportional regression models [hazard ratios (HR) and 95% confidence intervals (CI)] were used to examine the association between srPAD and the incidence of combined vascular events after adjusting for vascular risk factors and other potential confounders. Time to the first event among combined vascular events was the failure time. The failure time was censored either at death from nonvascular cause or the last follow-up. The 1,000 person-year event rate was calculated and compared between those with and without srPAD using the Poisson regression model. All statistical analyses were performed with SAS version 9.0 software (SAS Institute, Cary, NC). A p-value of less than 0.05 was considered significant.
RESULTS

Baseline Characteristics by Self-Reported PAD Status
Among 2,977 individuals, the mean age was 68.9±10.4 years; 64% were women; 54% were Hispanic, 25% were AfricanAmerican, and 21% were Caucasian. 002) . The Kaplan-Meier event-free survival curves for time to combined vascular events, incident MI, incident ischemic stroke, and vascular death are displayed in Fig. 1A-D. There was a significant difference in combined event-free survival between subjects with srPAD versus those without (log rank test p=0.0008) as well as for time to MI (log rank test p=0.003) and vascular death (log rank test p=0.018). However, no difference was detected in time to ischemic stroke between the two groups (log rank test p=0.604).
The relative risk of combined vascular events was increased by 48% in participants with srPAD (HR 1.48, 95% CI, 1.18-1.87) ( Table 2 ). After adjusting for age, sex, race-ethnicity, education level, hypertension, diabetes, LDL-C, and smoking, the risk of vascular events remained statistically significant (adjusted HR 1.35, 95% CI 1.06 to 1.74), as well as after additional adjustment for prior coronary revascularization and moderate alcohol consumption (adjusted HR 1.30, 95% CI 1.01-1.67).
DISCUSSION
Our results demonstrate a clear and independent association between self-reported PAD and the risk of future vascular events. An affirmative response to either of two PAD questions was associated with an adjusted 30% increased relative risk of ischemic stroke, MI, or vascular death. Other independent predictors of vascular outcomes in our multivariate analysis included age, male sex, hypertension, diabetes, and smoking. With the exception of cholesterol levels, the predictors for combined vascular outcomes in our study were similar to the coronary heart disease predictors used in the Framingham Heart equation 35 . Similarly, the Edinburgh Artery Study reported that the presence of PAD (defined by an ABI <0.9) was independently predictive of fatal MI after controlling for Our results indicate that the main difference in combined vascular outcomes between those with and without srPAD was largely attributable to an increased risk of MI and vascular death. These results are consistent with Framingham data demonstrating a strong association between intermittent claudication and coronary heart disease 21 . Our results, however, fail to show a clear relationship between srPAD and ischemic stroke. There are several possible explanations for this finding, including a lack of statistical power to detect differences in each outcome separately. Furthermore, PAD may be more closely associated with ischemic stroke due to large artery disease rather than other ischemic stroke subtypes, such as small vessel disease, which is more frequent in African-American and Hispanic populations 29 . Finally, this finding could also suggest that adverse outcomes in PAD patients may be driven by coronary heart disease events more than by ischemic stroke.
As reported in the literature, intermittent claudication is ascertained using validated questionnaires such as the Rose Claudication Questionnaire 37 ; however, these questionnaires have limited applicability to the busy primary care setting. Furthermore, the Rose Questionnaire has been demonstrated to have high specificity, but very low sensitivity 4, 5, 38, 39 . The PARTNERS (PAD Awareness, Risk and Treatment: New *Abbeviations: PAD, peripheral arterial disease †Model 1=self-reported PAD ‡Model 2=self-reported PAD adjusted for age, sex, race-ethnicity, and high school education §Model 3=Model 2 also adjusted for diabetes, hypertension, LDL-C, and smoking ║Model 4=Model 3 also adjusted for moderate alcohol consumption and prior coronary revascularization Resources for Survival) program, which was conducted in primary care practices throughout the US, reported a positive Rose questionnaire in only 8.7% of patients with PAD as determined by ABI <0.9. Notably, over half of these patients exhibited leg symptoms other than classic Rose claudication 5 .
Aside from its ease of use, our Question 1 (Do you get pain in the back of your legs when you walk that stops with rest?) is designed to detect symptoms of intermittent claudication while also capturing atypical exertional leg symptoms. This would be expected to result in significantly increased sensitivity and hence be more appropriate for screening purposes in the primary care setting. Simply asking this question is particularly important given that one study revealed that up to onethird of patients do not even alert a physician to their leg symptoms as they attribute them to musculoskeletal pain, arthritis, or aging 22 . In that same study, patients with objective PAD also demonstrated one or more co-morbidities, such as neuropathy, arthritis, and spinal stenosis. These co-morbidities can mask or alter the symptoms of classic claudication and, as a consequence, providers may be less likely to consider the diagnosis of PAD in these patients. Our Question 2 (Have you been told you have vascular (arterial) disease in the legs?) was designed to simply elicit the history of a prior PAD diagnosis directly from participants, a crucial first step in identifying those at higher risk. However, this question has yet to be incorporated into the routine general medicine history. A study aimed at assessing the factors affecting the diagnosis of PAD revealed that only 37% of internists reported taking a history of claudication; in contrast 92% reported taking a cardiac history most of the time (75-100% of the time) 23 . Similarly, PARTNERS reported that while 83% of patients with prior PAD were aware of their diagnosis, only 49% of their physicians were aware of this diagnosis 5 . Furthermore, prior studies have reported undertreatment of risk factors in PAD patients as compared to patients with CAD 5, 40 , highlighting the need for increased PAD awareness in primary care, where implementation of prevention measures could improve outcomes.
Prospective data linking the presence of PAD to adverse vascular events in large multi-ethnic populations remain scarce. This current study represents an opportunity to examine the association between PAD and vascular outcomes in a predominantly non-white population. In contrast to prior studies, we found that the prevalence of srPAD was significantly higher in Hispanics than in whites 41, 42 . The majority of Hispanics included in prior studies were Mexican-Americans 43 , while the Hispanics in our study are mainly Caribbean Hispanics. The high prevalence of srPAD within this subgroup may be attributable to an excess of traditional cardiovascular risk factors, but also perhaps to other unknown factors. More data are needed to characterize PAD prevalence among different Hispanic subgroups.
The screening methods for detection of PAD are not standardized. PAD management guidelines recommend the routine use of ABIs in general medicine practices 26 . However, the US Preventive Services Task Force currently recommends against routine screening for PAD by ABI testing 43 . Moreover, in a recent survey, time constraints (56%), lack of reimbursement (45%), and staff availability (45%) were major barriers to the use of screening ABIs 27 . Given the potential burden of performing ABIs in busy practices, we suggest using selfreported PAD as an initial screening tool to identify higher risk patients. Positive answers to the PAD questions should lead the physician to obtain more objective testing, such as ABIs. Confirmation of PAD by such testing would then in turn change treatment and monitoring goals for these patients.
The major limitation of our study is that ABI data were not available. The comparison study is currently underway and will provide an assessment of the relationship between selfreported PAD, ABIs, and vascular outcomes in this multiethnic cohort. The National Health and Nutrition Examination Survey (NHANES), a cross-sectional US survey of 2,174 individuals, reported a prevalence of PAD (defined as ABI <0.9) of 14.5% in those over age 70 44 . Our cohort was of a similar age (mean age 68.7 years) as this NHANES subgroup and was found to have a similar overall prevalence of srPAD of 15%. This suggests that the prevalence of self-reported PAD may correlate reasonably well with the prevalence of PAD as determined by ABI.
Another limitation of our study is a possibility of missing or misclassifying the outcomes since the adjudication of events from the hospital records and death certificates is a difficult process that includes reviewing the records, which are not always complete or accurate. However, the incidence rates of events in our study are comparable to other US populations of similar demographics.
CONCLUSION
Our two simple questions evaluating self-reported PAD are practical and easy to implement. In the absence of an official recommendation by the US Preventive Services Task Force for routine screening of PAD in high-risk patients 43 , the routine use of our questions by primary care physicians may represent a first step in identifying high-risk individuals who would benefit from objective testing for PAD and subsequent aggressive risk factor modification for prevention of MI, stroke, and vascular death.
